Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033)
Authors:
Open Access
- 20 September 2016
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 18 (1) , 1-13
Abstract
Family history of breast cancer is associated with an increased risk of contralateral breast cancer (CBC) even in the absence of mutations in the breast cancer susceptibility genes BRCA1/2. We compared quality-adjusted survival after contralateral prophylactic mastectomy (CPM) with surveillance only (no CPM) among women with breast cancer incorporating the degree of family history. We created a microsimulation model for women with first-degree, second-degree, and no family history treated for a stage I, II, or III estrogen receptor (ER)-positive or ER-negative breast cancer at the ages of 40, 50, 60, and 70. The model incorporated a 10-year posttreatment period for risk of developing CBC and/or dying of the primary cancer or CBC. For each patient profile, we used 100,000 microsimulation trials to estimate quality-adjusted life expectancy for the clinical strategies CPM and no CPM. CPM showed minimal improvement on quality-adjusted life expectancy among women age 50–60 with no or a unilateral first-degree or second-degree family history (decreasing from 0.31 to –0.06 quality-adjusted life-years (QALYs)) and was unfavorable for most subgroups of women age 70 with stage III breast cancer regardless of degree of family history (range –0.08 to –0.02 QALYs). Sensitivity analysis showed that the highest predicted benefit of CPM assuming 95 % risk reduction in CBC was 0.57 QALYs for a 40-year-old woman with stage I breast cancer who had a first-degree relative with bilateral breast cancer. Women age 40 with stage I breast cancer and a first-degree relative with bilateral breast cancer have a QALY benefit from CPM similar to that reported for BRCA1/2 mutation carriers. For most subgroups of women, CPM has a minimal to no effect on quality-adjusted life expectancy, irrespective of family history of breast cancer.Keywords
Funding Information
- Patient-Centered Outcomes Research Institute (CE-1304-6293)
This publication has 50 references indexed in Scilit:
- Long-Term Patient-Reported Satisfaction after Contralateral Prophylactic Mastectomy and Implant ReconstructionAnnals of Surgical Oncology, 2013
- Risk of Asynchronous Contralateral Breast Cancer in Noncarriers of BRCA1 and BRCA2 Mutations With a Family History of Breast Cancer: A Report From the Women's Environmental Cancer and Radiation Epidemiology StudyJournal of Clinical Oncology, 2013
- Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutationsThe American Journal of Surgery, 2011
- Cost-Effectiveness of Contralateral Prophylactic Mastectomy Versus Routine Surveillance in Patients With Unilateral Breast CancerJournal of Clinical Oncology, 2011
- Declining Incidence of Contralateral Breast Cancer in the United States From 1975 to 2006Journal of Clinical Oncology, 2011
- Health outcomes in economic evaluation: the QALY and utilitiesBritish Medical Bulletin, 2010
- Surveillance of prophylactic mastectomyCancer, 2009
- Second Primary Breast Cancer Occurrence According to Hormone Receptor StatusJNCI: Journal of the National Cancer Institute, 2009
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Clinical and histological predictors of contralateral breast cancerEuropean Journal of Surgical Oncology, 1999